Briacell Therapeutics - 30BCTXZPreferred / convertible
13F holders, Q2 2026 (June 30)5holders +1
3new positions
2sold out
$0.10avg. 13F price*
At the end of Q2 2026, 5 institutions reported holding Briacell Therapeutics - 30 (BCTXZ) in their 13F filings, up 1 from Q1 2026. 3 opened new positions and 2 sold out. The largest holders were Heights Capital Management, Inc. ($31K), Sabby Management, LLC ($11K) and Susquehanna International Group, LLP ($11K).
- Company
- Briacell Therapeutics - 30
- CUSIP
- 107930117
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $19K |
| Exits | 2 | $94K |
All 13F filers, Q1 2026 → Q2 2026: 197,517 shares bought and 983,967 shares sold, net −786,450 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Heights Capital Management, Inc. | — | Reduce -42.0% | 313,379 | $31K |
| Sabby Management, LLC | — | Reduce -41.6% | 120,802 | $11K |
| Susquehanna International Group, LLP | — | New | 114,522 | $11K |
| HRT Financial LP | — | New | 67,935 | $6K |
| Two Sigma Securities, LLC | — | New | 15,060 | $1K |
"% of holder's portfolio" is BCTXZ's weight in each manager's 13F, not the share of Briacell Therapeutics - 30 the manager owns.